CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Last trade$73.32
Day change-$0.40 (-0.54%)
Day range$72.25 – $75.85
Volume475,294
Market cap$3.87B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.87B
Price / earnings
30.11×
Price / book
8.29×
Price / sales
7.79×
EV / sales
7.28×
EV / EBITDA
165.26×
Profitability
Earnings per share
$2.45
Return on assets
20.05%
Return on equity
27.52%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.31×
Quick ratio
2.25×
Cash ratio
1.8×
Cash flow
Price / cash flow
56.12×
Price / free cash flow
64.82×
Free cash flow
$59.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CDNA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$139.36M
$131.95M
$117.7M
$108.39M
$100.06M
$86.68M
$84.69M
$86.58M
Cost of revenue
$40.29M
$34.97M
$33.63M
$35.51M
$30.65M
$28.66M
$28.42M
$28.19M
Gross profit
$99.08M
$96.98M
$84.07M
$72.87M
$69.4M
$58.02M
$56.27M
$58.39M
Selling, general and administrative
$69.64M
$74.35M
$60.86M
$59.61M
$52.88M
$51.96M
$45.76M
$53.69M
Research and development
$21.32M
$22.38M
$21.42M
$19.31M
$16.77M
$16.83M
$18.52M
$16.62M
Total operating expenses
$90.96M
$96.73M
$82.87M
$78.91M
$69.65M
$69.14M
$69.64M
-$25.99M
Operating income
$8.11M
$257K
$1.2M
-$6.04M
-$246K
-$11.12M
-$13.37M
$84.38M
Interest expense
$2.21M
$1.74M
$1.91M
$0
$2.01M
$2.36M
$2.78M
$0
Income before taxes
$10.69M
$114.52M
$2.78M
-$3.76M
$1.66M
-$8.69M
-$10.3M
$87.87M
Income taxes
-$8.6M
$3.88M
-$32.01K
$345K
-$15K
-$117K
$58K
$171K
Net income
$19.29M
$110.64M
$2.81M
-$4.11M
$1.68M
-$8.57M
-$10.35M
$87.7M
Net income attributable to common shareholders
$19.29M
$110.64M
$2.81M
-$4.11M
$1.68M
-$8.57M
-$10.35M
$87.7M
EBITDA
$15.32M
$3.07M
$5.7M
-$2.16M
$3.57M
-$7.05M
-$4.41M
-$8.56M
Basic earnings per share
$0.37
$2.15
$0.05
-$0.08
$0.03
-$0.16
-$0.19
$1.61
Diluted earnings per share
$0.35
$2.07
$0.05
-$0.08
$0.03
-$0.16
-$0.19
$1.26
Recent news
Company coverage with links to the original publishers.
CareDx (CDNA) has a consensus price target of $94.43, suggesting 28.1% upside potential from its current price of $73.72. The stock has gained 9.9% over the past four weeks and holds a Zacks Rank #1 (Strong Buy) rating. Analysts have revised earnings estimates higher, with one positive revision in the last 30 days and a 113.8% increase in consensus estimates. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as they are often overly optimistic.
CareDx (CDNA) has been upgraded to Zacks Rank #1 (Strong Buy) following a significant 110.6% increase in consensus earnings estimates over the past three months. The molecular diagnostics company is positioned in the top 5% of Zacks-covered stocks based on earnings estimate revisions, suggesting potential near-term stock price appreciation.
CareDx raised its 2026 revenue guidance to $520M-$530M and adjusted EBITDA outlook to $90M-$100M, driven by strong transplant testing demand with volumes up 21% to 50,750. The company's specialty oncology business (NavDx) contributed $12.5M in Q3 revenues with 37% year-over-year growth. Management is preparing new molecular diagnostics AlloHeme and HistoMap Kidney for 2027 commercialization while targeting higher reimbursement rates per test.
CareDx stock surged over 22% after reporting strong Q3 2026 earnings with 39% revenue growth to $139 million, driven by a 65% jump in testing services revenue and 51% increase in testing volumes. The company raised its full-year revenue guidance to $525 million (38% growth) and boosted adjusted EBITDA targets to $90-100 million, reflecting growing clinical interest in precision medicine diagnostics.
CareDx reported Q3 2026 earnings of $0.7 per share, significantly beating the consensus estimate of $0.24 and surpassing revenues by 13.90%. The stock has gained 282.9% year-to-date, outperforming the S&P 500's 13.1% gain. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 40% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.